Want to see AVTX full AI Analyst Report?
Total Valuation
Avalo Therapeutics has a market cap or net worth of $1.01B. The enterprise value is $151.27M.
Market Cap$1.01B
Enterprise Value$151.27M
Share Statistics
Avalo Therapeutics has 52,565,570 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding52,565,570
Owned by Insiders0.72%
Owned by Institutions40.95%
Financial Efficiency
Avalo Therapeutics’s return on equity (ROE) is -0.94 and return on invested capital (ROIC) is -70.18%.
Return on Equity (ROE)-0.94
Return on Assets (ROA)-0.67
Return on Invested Capital (ROIC)-70.18%
Return on Capital Employed (ROCE)-0.70
Revenue Per Employee1.79K
Profits Per Employee-2.37M
Employee Count33
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Avalo Therapeutics is ―. Avalo Therapeutics’s PEG ratio is -0.09.
PE Ratio―
PS Ratio4125.96
PB Ratio2.93
Price to Fair Value2.93
Price to FCF-4.73
Price to Operating Cash Flow-6.72
PEG Ratio-0.09
Income Statement
In the last 12 months, Avalo Therapeutics had revenue of 59.00K and earned -78.26M in profits. Earnings per share was -5.84.
Revenue59.00K
Gross Profit59.00K
Operating Income-72.92M
Pretax Income-78.09M
Net Income-78.26M
EBITDA-77.75M
Earnings Per Share (EPS)-5.84
Cash Flow
In the last 12 months, operating cash flow was -59.69M and capital expenditures 0.00, giving a free cash flow of -59.69M billion.
Operating Cash Flow-59.69M
Free Cash Flow-59.69M
Free Cash Flow per Share-1.14
Dividends & Yields
Avalo Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.13
52-Week Price Change307.14%
50-Day Moving Average16.59
200-Day Moving Average16.06
Relative Strength Index (RSI)63.85
Average Volume (3m)1.87M
Important Dates
Avalo Therapeutics upcoming earnings date is Jul 30, 2026, TBA (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Avalo Therapeutics as a current ratio of 8.14, with Debt / Equity ratio of 3.41%
Current Ratio8.14
Quick Ratio8.14
Debt to Market Cap<0.01
Net Debt to EBITDA0.17
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Avalo Therapeutics has paid 165.00K in taxes.
Income Tax165.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Avalo Therapeutics EV to EBITDA ratio is -2.96, with an EV/FCF ratio of -4.47.
EV to Sales3.90K
EV to EBITDA-2.96
EV to Free Cash Flow-4.47
EV to Operating Cash Flow-4.47
Balance Sheet
Avalo Therapeutics has $81.99M in cash and marketable securities with $2.33M in debt, giving a net cash position of $79.67M billion.
Cash & Marketable Securities$81.99M
Total Debt$2.33M
Net Cash$79.67M
Net Cash Per Share$1.52
Tangible Book Value Per Share$5.41
Margins
Gross margin is -34928.81%, with operating margin of -123601.69%, and net profit margin of -132642.37%.
Gross Margin-34928.81%
Operating Margin-123601.69%
Pretax Margin-132362.71%
Net Profit Margin-132642.37%
EBITDA Margin-131779.66%
EBIT Margin-132362.71%
Analyst Forecast
The average price target for Avalo Therapeutics is $44.90, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$44.90
Price Target Upside211.16% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast-86.62%
EPS Growth Forecast-1121.44%